SMMT · Summit Therapeutics Inc. · Executive Compensation
$15.55
+0.22 (+1.44%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Jul 23, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jul 23, 2026
Market Cap
$11.85B
Shares
797.75M
Volume · Oct 27
5.04M
Avg daily vol (3M)
6.06M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Manmeet Soni | Chief Operating Officer, Chief Financial Officer and Director | $249,127,782 |
| Mahkam Zanganeh | Co-Chief Executive Officer, President and Director | $246,047,279 |
| Robert Duggan | Co-Chief Executive Officer and Chairman | $172,376 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Manmeet Soni | Chief Operating Officer, Chief Financial Officer and Director | $4,772,489 |
| Mahkam Zanganeh | Co-Chief Executive Officer, President and Director | $1,161,021 |
| Ankur Dhingra | Former Chief Financial Officer | $256,280 |
| Robert Duggan | Co-Chief Executive Officer and Chairman | $158,613 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Manmeet Soni | Chief Operating Officer, Chief Financial Officer and Director | $23,613,339 |
| Mahkam Zanganeh | Co-Chief Executive Officer, President and Director | $20,562,924 |
| Ankur Dhingra | Former Chief Financial Officer | $621,251 |
| Robert Duggan | Co-Chief Executive Officer and Chairman | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Ankur Dhingra | Former Chief Financial Officer | $1,362,850 |
| Mahkam Zanganeh | Co-Chief Executive Officer, President and Director | $1,242,049 |
| Robert Duggan | Co-Chief Executive Officer and Chairman | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Mahkam Zanganeh | Director, Chief Executive Officer, and President | $9,639,214 |
| David Powell | Former Chief Scientific Officer | $1,606,698 |
| Jeffrey Maranian | Principal Accounting Officer | $1,044,147 |
| Robert Duggan | Chief Executive Officer and Executive Chairman | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Michael Donaldson | Chief Financial Officer ^^ | $961,418 |
| Ventzislav Stefanov | Former Executive Vice President, President of Discuva and Director ^^ | $674,823 |
| Glyn Edwards | Former Chief Executive Officer and Director ^^ | $621,822 |
| Mahkam Zanganeh | Director, co-Chief Executive Officer, and President | $527,312 |
| David Powell | Former Chief Scientific Officer | $401,124 |
| Robert Duggan | Chief Executive Officer and Executive Chairman | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Glyn Edwards | Former Chief Executive Officer and Director ^^ | $871,908 |
| Robert Duggan | Chief Executive Officer and Executive Chairman ^^ | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jeff Huber | director | Appointed | 2024-06-27 |
| Ujwala Mahatme | member of the Board of Directors | Resigned | 2024-06-17 |
| Mostafa Ronaghi | director | Appointed | 2024-04-11 |
| Bhaskar Anand | Chief Accounting Officer, Head of Finance | Appointed | 2024-04-03 |
| Manmeet Soni | Chief Financial Officer | Appointed | 2024-04-03 |
| Ankur Dhingra | Chief Financial Officer | Resigned | 2024-04-03 |
| Fong Clow | Chief Biometrics Officer | Appointed | 2023-10-16 |
| Allen S. Yang | Chief Medical Officer | Appointed | 2023-10-16 |
| Urte Gayko | Chief Regulatory, Quality, & Pharmacovigilance Officer | Appointed | 2023-10-16 |
| Dave Gancarz | Chief Business & Strategy Officer | Appointed | 2023-10-16 |
| Manmeet S. Soni | Chief Operating Officer | Appointed | 2023-10-16 |
| Michelle Xia | board of directors | Appointed | 2023-01-20 |
| Dr. Yu (Michelle) Xia | member of the Board | Appointed | 2023-01-20 |
| Dr. Michelle Xia | board of directors | Appointed | 2022-12-06 |
| Alessandra Cesano | director | Appointed | 2022-11-17 |
| Urte Gayko | Board of the Company | Resigned | 2022-10-03 |
| Robert Booth, PhD | director of Summit Therapeutics Inc. | Appointed | 2022-10-03 |
| Dr. Maky Zanganeh | Co-Chief Executive Officer and President | Appointed | 2022-07-26 |
Leadership
- Glyn Edwards CEO
- Mahkam Zanganeh CEO, COO, Board Member
- Robert Duggan CEO, Board Member
- Manmeet Soni CFO, Board Member
- Dr. Mahkam Zanganeh COO, Board Member
- Manmeet S. Soni COO
- Bhaskar Anand Chief Accounting Officer
- Jeffrey R. Maranian Chief Accounting Officer
- Alessandra Cesano Board Member
- Dr. Alessandra Cesano, MD, PhD Board Member
- Dr. Michael Wang Board Member
- Dr. Michelle Xia Board Member
- Dr. Robert Booth, PhD Board Member
- Dr. Yu (Michelle) Xia Board Member
- Jeff Huber Board Member
- Kenneth A. Clark Board Member
- Michelle Xia Board Member
- Mostafa Ronaghi Board Member
- Mostafa Ronaghi, PhD Board Member
- Robert Booth Board Member
- Robert Booth, PhD Board Member
Key facts
CIK
1599298
CUSIP
86627T108
13F (30d)
48 filings
48 filers
Visit website
Investor relations